IGF Research
IGF-1 DES: Truncation & Binding-Protein Effects
Reference check: 7 October 2026
Explore the shortened IGF-I analogue and why reduced binding to IGF-binding proteins can change a laboratory response without proving a clinical benefit.
Greater activity in a particular assay is not a universal measure of potency, duration or human effectiveness.
What DES identifies
Des(1–3)IGF-I refers to an insulin-like growth factor-I analogue missing the first three residues of the mature sequence. This is a structural description; it should not be confused with other IGF analogues or fragments.
IGF-binding proteins influence how much ligand is available in a biological system. Altering ligand interactions with those proteins can change an assay response even when the interpretation is more complex than a simple increase in receptor affinity.
What a cell study investigated
A primary investigation in rat granulosa cells compared intact IGF-I with the truncated analogue in a binding-protein context. It examined a defined cellular hormone-related endpoint. The result illustrates why the surrounding proteins influence apparent activity. [1]
That setting does not establish how the analogue behaves in every tissue, species or person. It also does not prove that the compound produces a predictable muscle-growth outcome or a clinically useful duration of action.
Make the assay context visible
When interpreting a comparison, ask whether binding proteins were present, whether free ligand exposure was considered and whether cell viability was examined. Apparent potency can depend on those choices.
A receptor-binding measurement and a cellular proliferation endpoint describe different steps. One cannot automatically replace the other. Broad claims about enhanced bioavailability should specify the system and measurement supporting them.
Identity and the limits of translation
A supplied preparation should be characterized against the actual truncated sequence and its relevant structural properties. A label mentioning IGF alone is incomplete for matching a sample to this literature.
This overview supports reading growth-factor experiments. It does not establish personal-use safety, recommend a route of administration or present a research analogue as a validated treatment or performance aid.
Questions to bring to the evidence
- Did the study control for IGF-binding proteins in the assay?
- Was the claimed potency measured at the receptor or inferred from a later endpoint?
Sources & further reading
- Truncated IGF-I and binding-protein effects in rat granulosa cellsPrimary cell-culture study